Journal Title：Drug Safety

Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:

Overviews of contentious or emerging issues.

Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes.

In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area.

Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.

Editorials and commentaries on topical issues.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

《藥物安全》是國際藥物警戒協(xié)會的官方期刊。該期刊包括：

有爭議或新興問題的概述。

全面的敘述性評論，提供有關流行病學、臨床特征、預防和管理個別藥物和藥物類別不良反應的權威信息來源。

對特定治療領域中藥物的不良反應和療效數據進行深入的效益風險評估。

系統(tǒng)評價（有或沒有薈萃分析），使用 PRISMA 聲明概述的明確、系統(tǒng)方法，匯總經驗證據以回答特定研究問題。

原創(chuàng)研究文章，報告藥物流行病學、藥物警戒、藥理學和毒理學以及藥物基因組學等學科精心設計的研究結果。

關于熱點問題的社論和評論。

其他數字功能（包括動畫摘要、視頻摘要、幻燈片、可以隨文章發(fā)布音頻幻燈片、教學視頻、信息圖表、播客和動畫；這些旨在提高期刊內容的可見性、讀者群和教育價值。此外，在《藥物安全藥物》上發(fā)表的文章可能會附有通俗易懂的摘要，以幫助對該領域有一定了解但不具備深入專業(yè)知識的讀者了解重要的醫(yī)學進展。

Drug Safety創(chuàng)刊于1986年，由Springer International Publishing出版商出版，收稿方向涵蓋醫(yī)學 - 毒理學全領域，此刊是該細分領域中屬于非常不錯的SCI期刊，在行業(yè)細分領域中學術影響力較大，專業(yè)度認可很高，所以對原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質量很高，可以嘗試。平均審稿速度 較慢,6-12周 ，影響因子指數4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。